Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
Healthcare
$26.93 -1.12%
-$0.34 today
- Market cap
- $1.76B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
52W Low $11.17High $40.22
Volume 0.64M
Average 0.64M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$45.59M
FY 2025 · Annual
Investing Cash Flow
-$186.81M
FY 2025 · Annual
Financing Cash Flow
$97.39M
FY 2025 · Annual
-25.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| Deferred Income Tax | 172K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.45M | 22.85M | 25.26M | 27.47M | 32.24M |
| Change in Working Capital | 46K | 43.02M | (6.03M) | (28.14M) | 16.35M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (4.27M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.9M | 121K | (3.21M) | 3.09M | 21.29M |
| Other Working Capital | (2.85M) | 42.9M | (2.82M) | (31.23M) | (675K) |
| Other Non-Cash Items | 1.26M | 1.78M | 1.94M | 623K | 2.12M |
| Operating Cash Flow | (66.91M) | (31.87M) | (81.07M) | (86.85M) | 45.59M |
| Capital Expenditures | (1.2M) | (3.96M) | (1.62M) | (203K) | (670K) |
| Acquisitions (Net) | 75.23M | 45.34M | 0 | 0 | 0 |
| Purchases of Investments | (87.23M) | (201.32M) | 0 | (167.27M) | (322.72M) |
| Sales of Investments | 12M | 159.4M | 107.56M | 60M | 136.58M |
| Other Investing Activities | (75.23M) | (45.34M) | 0 | 0 | 0 |
| Investing Cash Flow | (76.43M) | (45.88M) | 105.95M | (107.48M) | (186.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.29M | 45.34M | 52.08M | 128.84M | 97.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | 1.07M | 926K | 2.25M | 0 |
| Financing Cash Flow | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (142.05M) | (31.34M) | 77.89M | (63.23M) | (43.84M) |
| Free Cash Flow | (68.11M) | (35.83M) | (82.68M) | (87.05M) | 44.92M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$6.9M
+ D&A$1.8M
+ Stock-Based Comp$32.2M
+ Deferred Tax$0
+ Working Capital$16.3M
+ Other Non-Cash$2.1M
= Operating Cash Flow$45.6M
- Capex-$670.0K
= Free Cash Flow$44.9M
Analysis
FY2025 free cash flow is $44.9M. FCF conversion is -652.4% of net income. Operating cash flow was $45.6M, with capex of -$670.0K. The largest bridge item is Stock-Based Comp at $32.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Oct 29, 2026 |
Does STOK generate free cash flow?
Stoke Therapeutics, Inc. (STOK) generated $44.91M of free cash flow in fiscal 2025.
How much operating cash flow does STOK produce?
Operating cash flow was $45.59M, before capital expenditures of $670,000.00.
Continue the stock analysis
Jump to another research area for this company.